Weekly Anesthesiology Research Analysis
This week highlights advances spanning a high-impact preclinical non-opioid analgesic (β‑arrestin–biased NTSR1 modulator), randomized evidence improving hemodynamic safety during induction in severe aortic stenosis (cipepofol vs propofol), and a pragmatic surgical RCT showing hypovolemic phlebotomy expedites low‑CVP and reduces transection blood loss in open liver resection. Complementary themes include stronger methodology for AI/ML tools (selection-bias effects), perioperative neurocognitive p
Summary
This week highlights advances spanning a high-impact preclinical non-opioid analgesic (β‑arrestin–biased NTSR1 modulator), randomized evidence improving hemodynamic safety during induction in severe aortic stenosis (cipepofol vs propofol), and a pragmatic surgical RCT showing hypovolemic phlebotomy expedites low‑CVP and reduces transection blood loss in open liver resection. Complementary themes include stronger methodology for AI/ML tools (selection-bias effects), perioperative neurocognitive protection (esketamine, dexmedetomidine), and practical perioperative optimizations (BVM+PEEP preoxygenation, transtracheal lignocaine for intubation). These findings can shift device/drug choices and perioperative protocols in the near term.
Selected Articles
1. Arrestin-biased allosteric modulator of neurotensin receptor 1 alleviates acute and chronic pain.
Preclinical work identifies SBI-810, a β‑arrestin–biased positive allosteric modulator of NTSR1, as a potent analgesic across postoperative, inflammatory, and neuropathic rodent pain models. Analgesia depended on NTSR1 and β‑arrestin‑2, suppressed excitatory synaptic signaling (NMDA/ERK), reduced Nav1.7 surface expression and neuronal firing, attenuated C‑fiber responses, and decreased opioid reward/withdrawal behaviors.
Impact: Introduces a mechanistically distinct, non-opioid analgesic approach with both central and peripheral actions and favorable behavioral profile; represents a clear translational candidate to reduce opioid reliance.
Clinical Implications: Although preclinical, SBI‑810 motivates IND-enabling studies (GLP toxicology, PK/PD) and early-phase trials; if translatable, it could expand perioperative non-opioid analgesia and lessen opioid adverse effects and addiction risk.
Key Findings
- SBI-810 produced robust analgesia in postoperative, inflammatory, and neuropathic pain models via systemic and local routes.
- Analgesia required NTSR1 and β‑arrestin‑2 and involved suppression of NMDA/ERK signaling and reduced Nav1.7 surface expression.
- Behavioral endpoints showed reduced opioid reward, constipation, and withdrawal-like behaviors.
2. Hemodynamic Impact of Cipepofol vs Propofol During Anesthesia Induction in Patients With Severe Aortic Stenosis: A Randomized Clinical Trial.
In a single-center randomized trial of patients with severe aortic stenosis undergoing TAVR (n=122), equipotent cipepofol induced significantly smaller MAP deficit AUC over the first 15 minutes postinduction, lower incidence of postinduction hypotension (70.5% vs 88.5%), and reduced norepinephrine requirements compared with propofol at comparable BIS.
Impact: Provides randomized, clinically actionable evidence for an alternative induction agent that improves hemodynamic stability in a high‑risk cardiac population where induction hypotension is especially harmful.
Clinical Implications: Consider cipepofol as an induction agent option for severe aortic stenosis/TAVR patients to reduce immediate postinduction hypotension and vasopressor needs, while awaiting multicenter outcome data and local availability considerations.
Key Findings
- Smaller MAP deficit AUC in first 15 minutes postinduction with cipepofol (P<.001).
- Lower incidence of postinduction hypotension (70.5% vs 88.5%; P=.01).
- Reduced norepinephrine requirements during first 15 minutes (median 6.0 μg vs 10.0 μg; P=.006) at matched BIS.
3. Impact of Hypovolemic Phlebotomy with Low Central Venous Pressure on Intraoperative Blood Loss in Open Liver Resection: A Double-Blind Randomized Controlled Trial.
In a double-blind RCT (n=100), controlled hypovolemic phlebotomy to expedite low CVP during open liver resection reduced median parenchymal transection blood loss (300 vs 500 mL), shortened time to achieve low CVP (~50 vs 107.5 minutes), lowered surgical bleeding scores, and independently protected against >500 mL blood loss without increasing transfusion rates or postoperative complications.
Impact: Randomized evidence for an implementable anesthetic/surgical strategy that couples volume management to surgical field optimization and reduces bleeding burden during hepatectomy.
Clinical Implications: Teams performing open hepatectomy can adopt protocolized controlled phlebotomy to reach low CVP more rapidly as a blood-conservation approach, ensuring close hemodynamic monitoring and coordination between anesthesia and surgery.
Key Findings
- Reduced parenchymal transection blood loss with hypovolemic phlebotomy (median 300 vs 500 mL; P=0.02).
- Faster achievement of low CVP (median 50 vs 107.5 minutes; P=0.01).
- Lower surgical bleeding scores and independent protection against >500 mL blood loss (AOR 0.19).